News

Pharmaceutical giant Johnson & Johnson (NYSE: JNJ) is no stranger to legal issues. The company is still dealing with a barrage of lawsuits alleging that its talc-based products gave customers

We all love a good bargain, whether we're shopping for food, clothing -- or stocks. And even though the stock market has gained this year -- with the S&P 500 rising in the double digits -- there

As you may have heard this summer, Biogen (NASDAQ: BIIB) is taking out a $1.5 billion-dollar loan to fund its acquisition of rare disease drug developer Reata Pharmaceuticals (NASDAQ: RETA) for $7.3

Sometimes, the laws of physics seem to apply to the stock market. That's especially the case when it comes to momentum. When certain stocks get a head of steam going, it's hard to slow them down.

Certain stocks tend to perform better in a bull market, while others show their strengths in bear times. If you add both of these types of stocks to your portfolio, you're likely to benefit over the

If, like many other investors, you've written off big pharma stocks because of their reputation for being slow-growing giants, Vertex Pharmaceuticals (NASDAQ: VRTX) might be the breath of fresh air

September has historically been the worst month for the S&P 500, a phenomenon called the "September effect." The next few weeks may or may not live up (or down) to these low expectations, but

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) is firing on all cylinders. The company has performed better than the broader market in the past year as its core cystic fibrosis (CF) franchise

For any investment, getting it to $1 million can be a lofty goal to set. It's by no means an easy task, and will require a sizable buy-in, lots of patience, and good returns along the way. Below

Inflation is making life harder for everyone, including retirees who need to stretch out their savings to help cover additional costs. One way to help offset rising inflation is to invest in

If you're trying to build a passive income stream to eventually fuel your dream retirement, Abbott Laboratories (NYSE: ABT) is a stock you probably want to know more about. This legendary dividend

Unlike many of its big pharma peers, Eli Lilly (NYSE: LLY) is a growth stock that's likely to maintain a faster-than-average pace of expansion over the next few years. Between its massive portfolio

Though the pandemic isn't over, people haven't been rushing out to get coronavirus vaccines these days. This spring, the international public health emergency came to an end, and it looked as if we

Many investors are having a hard time finding good reasons to invest in Pfizer (NYSE: PFE) right now, at least if we go by the company's performance in the stock market this year. Pfizer's shares

On Aug. 23, CVS Health (NYSE: CVS) made waves when it announced that it will be launching a new business called Cordavis that will be devoted to commercializing biosimilar medicines. If you aren't

When's a good time to invest in dividend stocks? Any month that has a vowel in its name. 

We asked three Motley Fool contributors to identify no-brainer dividend stocks to buy in September. Here's

On Aug. 23, CVS Health (NYSE: CVS) announced that it's launching a new subsidiary focused on biosimilar drugs. That business, Cordavis, will start by seeking to commercialize a biosimilar to

Pfizer (NYSE: PFE) offered investors certainty in the earlier stages of the pandemic. People were clamoring for coronavirus vaccines and treatments, and Pfizer became a leader in both markets. Its

If you're wondering whether to buy Viatris (NASDAQ: VTRS) stock this fall, it's important to know the arguments for why it might gain value as well as why it's not the best option.

Generic drug

Are you a biotech investor who feels left behind? You're not alone. The broad Nasdaq Composite index has gained 13.7% since mid-May, but the Nasdaq Biotechnology index fell slightly over the same

Biogen (NASDAQ: BIIB) and Eli Lilly (NYSE: LLY) have a lot in common. Both companies are among the leaders in the biotech industry. Both have deep lineups and pipelines. And both are looking to

While government programs help retirees replace some of their income once they stop working, these initiatives aren't meant to fund all of people's expenses in their golden years. That's why many

Growth stocks are back in style after getting battered in last year's downturn. Some, though, never went out of fashion in the first place. That's the case with this trio of biotech stocks: Vertex

"I don't get no respect." That was the line the late comedian Rodney Dangerfield made famous. But it could also apply to some stocks.

Three Motley Fool contributors identified surprisingly

There's a lot going on with biotech giant Regeneron (NASDAQ: REGN) that may be of interest to investors. The company could soon face biosimilar competition from one of its key growth drivers, Eylea